BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 4064056)

  • 1. Further studies on the detection of early lung and breast carcinoma by T antigen.
    Springer GF; Fry WA; Desai PR; Semerdjian RA; Tegtmeyer H; Neybert CG; Scanlon EF
    Cancer Detect Prev; 1985; 8(1-2):95-100. PubMed ID: 4064056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fundamental and diagnostic role of T and Tn antigens in breast carcinoma at the earliest histologic stage and throughout.
    Springer GF; Desai PR; Robinson MK; Tegtmeyer H; Scanlon EF
    Prog Clin Biol Res; 1986; 204():47-70. PubMed ID: 2421349
    [No Abstract]   [Full Text] [Related]  

  • 3. [Thomsen antigen in human normal and tumor tissues].
    Berdinskikh MS; Pavliuchenkova RP; Kiseleva AS; Kulakova AM; Kosiakov PN
    Biull Eksp Biol Med; 1983 Mar; 95(3):59-61. PubMed ID: 6830988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T/Tn pancarcinoma autoantigens: fundamental, diagnostic, and prognostic aspects.
    Springer GF; Desai PR; Ghazizadeh M; Tegtmeyer H
    Cancer Detect Prev; 1995; 19(2):173-82. PubMed ID: 7750105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' immune response to breast and lung carcinoma-associated Thomsen-Friedenreich (T) specificity.
    Springer GF; Murthy SM; Desai PR; Fry WA; Tegtmeyer H; Scanlon EF
    Klin Wochenschr; 1982 Feb; 60(3):121-31. PubMed ID: 6176752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma.
    Springer GF; Desai PR; Spencer BD; Tegtmeyer H; Carlstedt SC; Scanlon EF
    Cancer Detect Prev; 1995; 19(4):374-80. PubMed ID: 7553680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with CA 15.3 as a tumor marker in breast cancer.
    Barros AC; Fry W; Nazario AC; Santos MO; Sato MK
    Eur J Surg Oncol; 1994 Apr; 20(2):130-3. PubMed ID: 8181577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients.
    Souchon R; Koppenhagen K; Souchon MF; Matthes M; Boese-Landgraf J; Fitzner R; Baer U
    Cancer Detect Prev; 1985; 8(1-2):101-9. PubMed ID: 3864534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA 15.3: early results of a new breast cancer marker.
    Colomer R; Sole LA; Navarro M; Encabo G; Ruibal A; Salvador L
    Anticancer Res; 1986; 6(4):683-4. PubMed ID: 3463242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung cancer patients' autoimmune responses to Thomsen-Friedenreich (T) antigen: diagnostic utility.
    Fry WA; Springer GF; Desai PR
    Klin Wochenschr; 1983 Aug; 61(16):817-8. PubMed ID: 6632723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [T antigen test of sputum--a new simple method for the screening of lung cancer].
    Li X; Dai X; He A
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):285-6, 317. PubMed ID: 8762480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral antitumor immune responses in patients with breast cancer measured with the leukocyte adherence inhibition technique.
    Kotlar HK; Sanner T
    J Natl Cancer Inst; 1981 Feb; 66(2):265-71. PubMed ID: 7005505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma.
    Imai J; Ghazizadeh M; Naito Z; Asano G
    Anticancer Res; 2001; 21(2B):1327-34. PubMed ID: 11396208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T antigen, a tumor marker against which breast, lung and pancreas carcinoma patients mount immune responses.
    Springer GF; Desai PR; Fry WA; Goodale RL; Shearen JG; Scanlon EF
    Cancer Detect Prev; 1983; 6(1-2):111-8. PubMed ID: 6883373
    [No Abstract]   [Full Text] [Related]  

  • 18. M34 actin regulatory protein is a sensitive diagnostic marker for early- and late-stage mammary carcinomas.
    Soriano Z; Pardee JD
    Clin Cancer Res; 2004 Jul; 10(13):4437-43. PubMed ID: 15240534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.
    Okita R; Saeki T; Takashima S; Yamaguchi Y; Toge T
    Oncol Rep; 2005 Nov; 14(5):1269-73. PubMed ID: 16211295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.